CHICAGO — Ensartinib shows promise for the treatment of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer, Makenzi Evangelist, MD, said at International Association for the Study of Lung Cancer Multidisciplinary Symposium in Thoracic Oncology.